Most Watched by Traders: Ultragenyx Pharmaceutical Inc., Pain Therapeutics Inc. (NASDAQ:PTIE), Ocata Therapeutics (NASDAQ:OCAT), Synthetic Biologics Inc. (NYSEMKT:SYN)


Autoliv, Inc. (NYSE:ALV) shares moved down -0.15% in last trading session and ended the day at $124.82. ALV Gross Margin is 19.90% and its has a return on assets of 5.70%. Autoliv, Inc. (NYSE:ALV) quarterly performance is 23.57%.

Autoliv, Inc. (NYSE:ALV) has appointed Mats Backman as Group Vice President and Chief Financial Officer. Mr. Backman brings more than 20 years of experience from different industries to Autoliv. Mr. Backman will assume his position with Autoliv during the first half of 2016.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) ended the last trading day at $94.93. Company weekly volatility is calculated as 6.72% and price to cash ratio as 8.22. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) showed a weekly performance of -8.51%.

Vetr downgraded shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) from a strong-buy rating to a buy rating in a research report published on Wednesday, Market Beat Ratings reports. The brokerage currently has $108.44 price objective on the biopharmaceutical company’s stock.

On 25 November, Pain Therapeutics Inc. (NASDAQ:PTIE) shares increased 1.04% and was closed at $1.94. PTIE EPS growth in last 5 year was -27.50%. Pain Therapeutics Inc. (NASDAQ:PTIE) year to date (YTD) performance is -4.43%.

On 9 November, Pain Therapeutics Inc. (NASDAQ:PTIE) reported financial results for the quarter ended September 30, 2015. Net loss in Q3 2015 was $3.7 million, or $0.08 per share, compared to a net loss in Q3 2014 of $3.5 million, or $0.08 per share.

Ocata Therapeutics, Inc. (NASDAQ:OCAT) shares increased 0.59% in last trading session and ended the day at $8.55. OCAT Gross Margin is 50.00% and its has a return on assets of -189.10%. Ocata Therapeutics, Inc. (NASDAQ:OCAT) quarterly performance is 126.79%.

On 18 November, Ocata Therapeutics, Inc. (NASDAQ:OCAT) said that, its CEO Paul Wotton told investors that results expected within a few months from an ongoing mid-stage trial “could be a value creating event for the company.”

Synthetic Biologics Inc. (NYSEMKT:SYN) caters to the Healthcare space. Its weekly performance is 37.21%. On the last day of trading company shares ended up at $2.95. Synthetic Biologics Inc. (NYSEMKT:SYN) distance from 50-day simple moving average (SMA50) is 19.77%.

Synthetic Biologics Inc. (NYSEMKT:SYN) announced that Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at the University of California, Los Angeles (UCLA) David Geffen School of Medicine, and the lead principal investigator of the Phase 2 clinical trial that evaluated Trimesta™ as a treatment for relapsing-remitting multiple sclerosis (RRMS) in women, published additional clinical trial data in the journal, Lancet Neurology.


Leave a Reply

Your email address will not be published. Required fields are marked *